Martin K. Yau
FDA investigator
Appears on 4 documents from 2004 to 2011, mostly at sites in Texas. Most often cites analytical methods for an in vivo bioavailability or bioequivalence study (21 CFR 320.29).
- 4
- Documents on file
- 6.0
- Observations per 483
- 2004
- First seen
- 2011
- Most recent
What they cite most
From 6 observations- 21 CFR 320.29Analytical methods for an in vivo bioavailability or bioequivalence study1
Activity by year
2004: 2, 2010: 1, 2011: 1
Where
Texas 2 · Canada 1 · Pennsylvania 1
Often inspects with
Is Martin K. Yau coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
4 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2011-07-26 | Warning letter Cetero ResearchJul 26, 2011 · Houston, Texas | Houston, Texas | — | |
| 2010-12-10 | 483 Cetero ResearchDec 10, 2010 · Houston, Texas | Houston, Texas | 6 | |
| 2004-12-21 | fda_correspondence MDS Pharma ServicesDec 21, 2004 · King of Prussia, Pennsylvania | King of Prussia, Pennsylvania | — | |
| 2004-04-26 | Warning letter MDS Pharma ServicesApr 26, 2004 · Saint-Laurent, Canada | Saint-Laurent, Canada | — |
About this profile
What does Martin K. Yau inspect?
Martin K. Yau appears on 4 documents on file covering 1 site, mostly in Texas.
What do they cite most often?
21 CFR 320.29 (analytical methods for an in vivo bioavailability or bioequivalence study).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Martin K. Yau is dated Jul 26, 2011.